Dr. Alex Matter       CML          Chronic  Myeloid Leukemia

''Dr. Alex Matter is best known for his contribution to the development of
Glivec/Gleevec, one of the world’s first tyrosine kinase inhibitor drugs against
chronic myeloid leukemia (CML). Starting in the mid-eighties, Dr. Matter led a
team of close to 200 scientists at Novartis to discover and optimize the lead
compound and brought it all the way through its first clinical trial in 1998. In
a short span of 3 years, Glivec/Gleevec was given a very rare, fast track FDA
approval in 2001.''
Extract of CV of  Alex Matter
ARTICLES

2013 Prize: Alex Matter, M.D.
April 6, 2013, National Foundation for Cancer Research
 
Dr. Alex Matter has been awarded the 8th  Annual Szent-Gyorgyi  Prize for Progress in Cancer Research
January 29, 2013, National Foundation for Cancer research

Executive Summary of a Book: Magic  Cancer Bullet
May 23, 2009, Discovery  Medecine                                       
                    
                                               See also History of CML
                                         Modes of access to the website
​
1 - Public access  (strongly recommended)
     On several occasions, the CML patient called CMLer will need a password  to access several modules of the website.  
                  (No registration required - Anonymous access)​
​2 - Reserved access to CMLeukemia private group
     On other occasions, the more experienced patients will need more up-to-date or in-depth information. Among other upcoming modules, they will need access to the archives and also to abstracts of congresses on CML.
​                  (Member password required and registration required).